Ctrl Tx
1 known investors
Ctrl-Tx develops cell therapies for solid tumors using cTRLs, a rare circulating T cell population isolated from a single blood draw via its proprietary IsoQore cell-sorting platform. The company engineers a polyclonal cell therapy intended to treat solid tumors without surgically removing tumor tissue.
BiotechHealthtech
Investors · 1
Frequently asked questions
- What does Ctrl Tx do?
- Ctrl-Tx develops cell therapies for solid tumors using cTRLs, a rare circulating T cell population isolated from a single blood draw via its proprietary IsoQore cell-sorting platform. The company engineers a polyclonal cell therapy intended to treat solid tumors without surgically removing tumor tissue.
- Who are Ctrl Tx's investors?
- Ctrl Tx's investors include Portal Innovations.